Skip to nav Skip to content

News Releases and Statements

Facebook Twitter LinkedIn Email

IDSA Honors 175 Distinguished Physicians, Scientists with FIDSA Designation

The nation’s leading infectious diseases professional society, recognizes the distinguished physicians and scientists from the United States and around the world who were elected this year to be Fellows of IDSA.

HIV Providers Call for Policy Reforms to End HIV as an Epidemic

IDSA and HIVMA say that while barriers to ending the HIV epidemic are significant, the goal could be within reach with broad-based policy reforms at the federal, state and local levels.

IDSA on New CDC Changes to Post-COVID-19 Infection Recommendations

Updated recommendations from the Centers for Disease Control and Prevention on masking and isolation post-COVID-19 infection are a positive sign that advances in vaccines and treatments have significantly lowered the risk of severe illness, hospitalization and death from the disease.

Monkeypox Bill Provides Crucial Steps Toward Equitable Access to Testing

IDSA applauds new legislation introduced by Rep. Sean Patrick Maloney (D-NY) to ensure monkeypox testing is available at no cost to the public.

Monkeypox Public Health Emergency Should Grant Flexibility to Expand Treatment and Vaccine Access

IDSA and HIVMA support the Biden Administration’s decision to declare the monkeypox outbreak a public health emergency.

IDSA and HIVMA Applaud New Administration Monkeypox Coordinators, Call for Funding and Improved Vaccine Supply and Access

As monkeypox cases top more than 5,800 across 48 states, there is no time to waste.

Senate Appropriations Bill Provides Boost to Fight Against AMR

IDSA is pleased to see that critical new investments to strengthen the federal fight against antimicrobial resistance were included in the fiscal year 2023 Labor, Health and Human Services appropriations bill released July 28.

IDSA Statement on Increase in Monkeypox Vaccine Supply

Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.

IDSA/HIVMA Support Rapid CDC Response to Monkeypox Treatment Access Issues

IDSA and HIVMA appreciate the CDC’s swift action in responding to health care provider concerns regarding the significant procedural barriers required to obtain tecovirimat, or TPOXX, through the Expanded Access for Investigational New Drug program.

Five Institutions Receive the IDSA Antimicrobial Stewardship Center of Excellence Designation

The five awarded institutions have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.

IDSA Launches Call for Applications for Next Editor-in-Chief of Open Forum Infectious Diseases

IDSA seeks candidates to serve in the position of editor-in-chief of OFID. The founding editor-in-chief of the journal, Paul Sax, MD, FIDSA, recently departed for a new role as editor-in-chief of IDSA’s journal CID.

U.S. Must Curb Rising Rate of Resistance to Antimicrobials

With rates of antimicrobial-resistant infections rising quickly, systemic changes are urgently needed to protect public health. This is no longer a future crisis but one that is at America’s doorstep and needs to be addressed now.

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.